Relmada Therapeutics (NASDAQ: RLMD)
$3.86
(-1.3%)
-$0.05
Price as of April 24, 2024, 4:00 p.m. ET
Relmada Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Relmada Therapeutics Company Info
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.
News & Analysis
Featured Article
Here's Why Relmada Therapeutics Stock Popped Today
Results from a human abuse potential study with REL-1017 exceeded expectations.
Cory Renauer | Jul 27, 2021
Featured Article
Is It Too Late to Buy These 3 Pharmaceutical Stocks?
Relmada Therapeutics, Neoleukin Therapeutics, and Durect were among the fastest-rising pharmaceutical stocks over the past year.
Jim Halley | Jul 7, 2020
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.